Stroke: 缺血性卒中血管内治疗适应症的预测因子

2016-06-30 phylis 译 MedSci原创

背景:血管内治疗(EVT)是大血管闭塞性卒中新的标准化的治疗。研究者旨在确定综合卒中中心符合静脉溶栓(IVT)和EVT条件的患者。并且,推导预测适合EVT治疗的预测因子。方法:从卒中中心登记的患者(2003-2014),入院24小时内常规检查,根据美国心脏协会/美国卒中协会(AHA/ASA)选择出能够确定IVT和EVT适应症的所有数据。此外,从随机对照试验和临床实践中选出较少限制性的标准。IVT(

背景:血管内治疗(EVT)是大血管闭塞性卒中新的标准化的治疗。研究者旨在确定综合卒中中心符合静脉溶栓(IVT)和EVT条件的患者。并且,推导预测适合EVT治疗的预测因子。

方法:从卒中中心登记的患者(2003-2014),入院24小时内常规检查,根据美国心脏协会/美国卒中协会(AHA/ASA)选择出能够确定IVT和EVT适应症的所有数据。此外,从随机对照试验和临床实践中选出较少限制性的标准。IVT(门-进针时间≤60分钟)和CVT(门-腹股沟≤90分钟)的适应症最大时间窗分别为3.5小时和4.5小时。Logistic回归分析人口统计学和临床信息以得到与EVT适应症相关的变量。

结果:共有2704例急性缺血性卒中患者,其中26.8%例为转诊。所有脑卒中患者到达综合卒中中心,符合IVT总比例为12.4%。根据AHA/ASA指南和较少限制的方法,所有急性缺血性脑卒中患者符合EVT分别为2.9%和4.9%,6小时内到达的缺血性卒中患者符合EVT分别为10.5% vs 17.7%。符合AHA-EVT适应症者,更年轻,发病到入院时间更短,国立卫生院卒中量表(NIHSS)更高,失眠,半侧忽视,无小脑体征、心房纤颤、吸烟者较低、血糖水平降低(ROC= 0.86)。

结论:患者6小时内到综合卒中中心,根据AHA/ASA标准,10.5%符合EVT适应症,根据类似的随机对照试验的标准,17.7%符合EVT适应症,符合IVT的治疗者是其2倍(36.2%)。

原始出处:

Vanacker P, Lambrou D2, et al. Eligibility and Predictors for Acute Revascularization Procedures in a Stroke Center. Stroke. 2016 Jun 14.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1806092, encodeId=2bfc180609204, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jul 14 21:25:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145961, encodeId=730e1459614f, content=赞了,认真探究、学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 22:29:08 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892769, encodeId=8e491892e69ee, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Oct 29 22:25:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310626, encodeId=585a13106268b, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat Jul 02 07:25:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336724, encodeId=433b1336e2446, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Sat Jul 02 07:25:00 CST 2016, time=2016-07-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1806092, encodeId=2bfc180609204, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jul 14 21:25:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145961, encodeId=730e1459614f, content=赞了,认真探究、学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 22:29:08 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892769, encodeId=8e491892e69ee, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Oct 29 22:25:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310626, encodeId=585a13106268b, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat Jul 02 07:25:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336724, encodeId=433b1336e2446, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Sat Jul 02 07:25:00 CST 2016, time=2016-07-02, status=1, ipAttribution=)]
    2016-10-11 ylzr123

    赞了,认真探究、学习。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1806092, encodeId=2bfc180609204, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jul 14 21:25:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145961, encodeId=730e1459614f, content=赞了,认真探究、学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 22:29:08 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892769, encodeId=8e491892e69ee, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Oct 29 22:25:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310626, encodeId=585a13106268b, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat Jul 02 07:25:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336724, encodeId=433b1336e2446, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Sat Jul 02 07:25:00 CST 2016, time=2016-07-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1806092, encodeId=2bfc180609204, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jul 14 21:25:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145961, encodeId=730e1459614f, content=赞了,认真探究、学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 22:29:08 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892769, encodeId=8e491892e69ee, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Oct 29 22:25:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310626, encodeId=585a13106268b, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat Jul 02 07:25:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336724, encodeId=433b1336e2446, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Sat Jul 02 07:25:00 CST 2016, time=2016-07-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1806092, encodeId=2bfc180609204, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jul 14 21:25:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145961, encodeId=730e1459614f, content=赞了,认真探究、学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 22:29:08 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892769, encodeId=8e491892e69ee, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Oct 29 22:25:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310626, encodeId=585a13106268b, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat Jul 02 07:25:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336724, encodeId=433b1336e2446, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Sat Jul 02 07:25:00 CST 2016, time=2016-07-02, status=1, ipAttribution=)]

相关资讯

Stroke:缺血性脑卒中,静脉溶栓联合血栓切除优于单独静脉溶栓治疗

背景:缺血性脑卒中患者的随机试验表明,与药物治疗相比(包括静脉溶栓),应用新一代的取栓装置的血管内治疗有更好的功能预后。然而,在常规临床实践中患者的死亡率及预后的普遍性尚不清楚。方法:在一项前瞻性观察性研究中,研究对象为进行静脉溶栓、取栓或联合治疗的缺血性脑卒中患者。主要预后是3个月改良Rankin量表评分(0 [无症状] -6 [死亡]分)在。采用有序逻辑回归法估计治疗效果(位移分析)的一般OR

PLoS One:急性缺血性脑卒中患者,高血浆hsCRP水平与不良临床预后独立相关

背景:尽管由于脑梗死后炎症反应使得血浆C反应蛋白(CRP)升高,但急性缺血性卒中后的C反应蛋白与临床预后的关系仍不明朗。本研究旨在探讨血浆高敏C反应蛋白(hsCRP)水平是否独立于传统的危险因素和急性卒中后感染,与临床结局相关。方法:研究者前瞻性纳入3653例首发缺血性脑卒,这些患者功能独立,并且症状开始24h内入院。入院时检测血浆hsCRP水平,将血浆hsCRP水平分为四分位数。采用Logist

Lancet Neurol:急性缺血性卒中可早期应用阿替普酶治疗

背景:随机试验表明,急性缺血性卒中患者4.5h内应用阿替普酶,可增加良好预后的的可能。然而,阿替普酶也增加脑出血的风险;研究者旨在确定不同类型患者,应用阿替普酶对脑出血,死亡率和功能损害风险的比例和绝对的影响。方法:研究者使用卒中溶栓试验(STT)中,阿替普酶与安慰剂或空白对照的随机试验的荟萃分析中,获取急性缺血性脑卒中患者的数据。研究这将脑出血预先分为三类:7天内2型脑实质出血;24-36 h出

J Stroke Cerebrovasc Dis:他汀药物可降低缺血性卒中感染发生的风险

目标:他汀类药物独立于其降脂作用具有免疫调节的作用和外周抗炎的特性。在临床研究中,这些性质是否降低卒中后感染风险尚不确定。研究者评估18岁以上住院的缺血性卒中患者,他汀类暴露对卒中后感染发生的风险。材料与方法:对急性护理医院电子病历进行回顾性分析。将患者分配到暴露队列,感染前应用他汀类药物,应用他汀药物治疗但未感染。未暴露队列包括未应用他汀类药物,或感染后应用他汀类药物。校正卒中后感染的危险因素条

Stroke:PASS量表可预测大动脉闭塞性缺血性卒中

背景:研究者设计并验证一个简单的院前卒中量表识别紧急大血管闭塞(ELVO)性缺血性脑卒中,并且与其他已经发表的预测ELVO的量表进行比较。方法:国家历史测试队列中的3127例患者,确认再灌注治疗前颅内血管状态(血管造影)。美国国立卫生院卒中量表(NIHSS)是预测颅内大动脉闭塞价值最高量表,确定院前符合预定标准的最优组合是可行的。比较院前急性卒中严重程度(PASS)量表和ELVO其他已发表的量表的

J Stroke Cerebrovasc Dis: 脑实质血肿2型与缺血性卒中溶栓后24h恶化相关

背景:静脉溶栓治疗可以改善急性缺血性卒中(AIS)神经功能预后,但存在出血性转化(HT)的风险。症状性脑出血(ICH)的目前的定义:有一定程度的相关的神经系统恶化。然而,早期继发性脑出血的有害影响,也可能表现为减少神经系统功能的改善。本研究旨在探讨是不同的影像类型的HT和溶栓后24小时神经功能改善程度之间是否独立相关。方法:这项研究是对AIS溶栓病例的中心数据库进行回顾性分析。校正潜在的混杂因素后